{"id":"https://openalex.org/W7202353097","doi":"https://doi.org/10.67209/hgcg2985","title":"Patients with relapsed or refractory multiple myeloma who achieved sustained minimal residual disease negativity in the DREAMM-7 trial","display_name":"Patients with relapsed or refractory multiple myeloma who achieved sustained minimal residual disease negativity in the DREAMM-7 trial","publication_year":2026,"publication_date":"2026-04-07","ids":{"openalex":"https://openalex.org/W7202353097","doi":"https://doi.org/10.67209/hgcg2985"},"language":"en","primary_location":{"id":"doi:10.67209/hgcg2985","doi":"https://doi.org/10.67209/hgcg2985","is_oa":false,"landing_page_url":"https://doi.org/10.67209/hgcg2985","pdf_url":null,"source":{"id":"https://openalex.org/S7407059019","display_name":"NCODA Oncology and Hematology Meeting Abstracts","issn_l":"3071-6462","issn":["3071-6462"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NCODA Oncology and Hematology Meeting Abstracts","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5147109028","display_name":"Mar.a-Victoria Mateos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mar.a-Victoria Mateos","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017586611","display_name":"Pawel J. Robak","orcid":"https://orcid.org/0000-0002-6078-5415","observed_orcids":["https://orcid.org/0000-0002-6078-5415"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pawe\u0142 Robak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033354752","display_name":"Marek Hus","orcid":"https://orcid.org/0000-0002-9036-6625","observed_orcids":["https://orcid.org/0000-0002-9036-6625"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marek Hus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040499157","display_name":"\u0416\u0435\u0440\u0435\u0431\u0446\u043e\u0432\u0430 \u0412\u0435\u0440\u0430 \u0410\u043d\u0430\u0442\u043e\u043b\u044c\u0435\u0432\u043d\u0430","orcid":"https://orcid.org/0000-0002-3052-269X","observed_orcids":["https://orcid.org/0000-0002-3052-269X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vera Zherebtsova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148695623","display_name":"Christopher Ward","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Ward","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009395461","display_name":"Phoebe Joy Ho","orcid":"https://orcid.org/0000-0002-2811-8671","observed_orcids":["https://orcid.org/0000-0002-2811-8671"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Joy Ho","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5147119520","display_name":"Roman H.jek","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roman H.jek","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5147117014","display_name":"Kihyun Kim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kihyun Kim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062322697","display_name":"Sebastian Grosicki","orcid":"https://orcid.org/0000-0003-2644-1050","observed_orcids":["https://orcid.org/0000-0003-2644-1050"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sebastian Grosicki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088943742","display_name":"Hanlon Sia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hanlon Sia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152392513","display_name":"Adam Bryant","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adam Bryant","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084502515","display_name":"Marcelo Pitombeira de Lacerda","orcid":"https://orcid.org/0000-0001-5554-7167","observed_orcids":["https://orcid.org/0000-0001-5554-7167"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marcelo Pitombeira de Lacerda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107438857","display_name":"Gracia Aparecida-Martinez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gracia Aparecida-Martinez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077430940","display_name":"Anna Maria Sureda","orcid":"https://orcid.org/0000-0002-1238-6970","observed_orcids":["https://orcid.org/0000-0002-1238-6970"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Sureda Balar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5147124599","display_name":"Jie Ma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jie Ma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057184094","display_name":"Yinjiao Ma","orcid":"https://orcid.org/0000-0003-1742-2026","observed_orcids":["https://orcid.org/0000-0003-1742-2026"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yinjiao Ma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110647052","display_name":"Maureen Nichols","orcid":"https://orcid.org/0000-0001-7865-3376","observed_orcids":["https://orcid.org/0000-0001-7865-3376"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maureen Nichols","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021644280","display_name":"Jorge L Mouro","orcid":"https://orcid.org/0000-0001-5978-9411","observed_orcids":["https://orcid.org/0000-0001-5978-9411"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jorge Mouro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053040180","display_name":"Zeyad Khalaf","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zeyad Khalaf","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113236473","display_name":"Hena Baig","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hena Baig","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020620994","display_name":"Benga Kazeem","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Benga Kazeem","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025863797","display_name":"Nick Pirooz","orcid":"https://orcid.org/0009-0006-4371-534X","observed_orcids":["https://orcid.org/0009-0006-4371-534X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nick Pirooz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5147068779","display_name":"Sybil Varghese","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sybil Varghese","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5147061827","display_name":"Joe Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joe Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066026746","display_name":"Lydia Eccersley","orcid":"https://orcid.org/0000-0002-2555-0725","observed_orcids":["https://orcid.org/0000-0002-2555-0725"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lydia Eccersley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113348821","display_name":"V\u00e2nia Hungria","orcid":"https://orcid.org/0000-0002-4327-1957","observed_orcids":["https://orcid.org/0000-0002-4327-1957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vania Hungria","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9279999732971191},{"id":"https://openalex.org/keywords/minimal-residual-disease-negativity","display_name":"minimal residual disease negativity","score":0.843999981880188},{"id":"https://openalex.org/keywords/belantamab-mafodotin","display_name":"belantamab mafodotin","score":0.9179999828338623},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9369999766349792},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9470000267028809},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9769999980926514},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.7360000014305115},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.578000009059906},{"id":"https://openalex.org/keywords/mrd-monitoring","display_name":"MRD monitoring","score":0.35600000619888306},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.578000009059906},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8840000033378601},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.30300000309944153}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9103000164031982},{"id":"https://openalex.org/C7453019","wikidata":"https://www.wikidata.org/wiki/Q16254302","display_name":"Negativity effect","level":2,"score":0.7178999781608582},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6212000250816345},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6072999835014343},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.4645000100135803},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.4406999945640564},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.42239999771118164},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.4097000062465668},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3919000029563904},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.36390000581741333},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.34369999170303345},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.32600000500679016},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3098999857902527},{"id":"https://openalex.org/C202953159","wikidata":"https://www.wikidata.org/wiki/Q382695","display_name":"Intention-to-treat analysis","level":3,"score":0.2791999876499176},{"id":"https://openalex.org/C2780084366","wikidata":"https://www.wikidata.org/wiki/Q37732","display_name":"Demographics","level":2,"score":0.27469998598098755},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.27410000562667847},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.2615000009536743},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.2614000141620636}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.67209/hgcg2985","doi":"https://doi.org/10.67209/hgcg2985","is_oa":false,"landing_page_url":"https://doi.org/10.67209/hgcg2985","pdf_url":null,"source":{"id":"https://openalex.org/S7407059019","display_name":"NCODA Oncology and Hematology Meeting Abstracts","issn_l":"3071-6462","issn":["3071-6462"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"NCODA Oncology and Hematology Meeting Abstracts","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":1,"referenced_works":["https://openalex.org/W4398143893"],"related_works":["https://openalex.org/W4417012482","https://openalex.org/W4405038457","https://openalex.org/W7162541824","https://openalex.org/W4410795580","https://openalex.org/W7108604932","https://openalex.org/W4412461073","https://openalex.org/W7204690948","https://openalex.org/W4391559535","https://openalex.org/W7202386603","https://openalex.org/W4399480854"],"abstract_inverted_index":{"Background:":[0],"In":[1],"DREAMM-7,":[2],"belantamab":[3],"mafodotin":[4],"(belamaf),":[5],"bortezomib,":[6,20],"and":[7,14,21,84,92,119,185,218,248,264,340,357,380,394,417,423],"dexamethasone":[8,22],"(BVd)":[9],"significantly":[10,45],"prolonged":[11],"progression-free":[12],"survival":[13,16],"overall":[15],"versus":[17],"(vs)":[18],"daratumumab,":[19],"(DVd)":[23],"in":[24,40,58,82,95,114,132,137,146,164,173,207,280,346,368],"patients":[25,39,70,105,124,138,165,174,210,233,270,284,313,326,345,381,408,416],"with":[26,166,286,291,296,314,399],"relapsed/refractory":[27],"multiple":[28],"myeloma":[29],"(RRMM)":[30],"after":[31,168],"\u22651":[32,169,213],"prior":[33,170,360],"line":[34],"of":[35,104,123,160,215,283,334,344,406,427,439],"therapy":[36],"(LOT).":[37],"Additionally,":[38],"the":[41,59,86,96,102,117,135,241,347,369,377,436],"BVd":[42,161,237,287,293,348,400],"arm":[43,61],"demonstrated":[44],"higher":[46,398,404,425],"complete":[47],"response":[48],"(CR)\u2013based":[49],"minimal":[50,74],"residual":[51,75],"disease":[52,76,90,121],"(MRD)":[53,77],"negativity":[54,78,110,129,143,192,198,231,277,305,390,413],"rates":[55,259,391,426],"vs":[56,162,245,252,262,266,288,306,309,354,363,366,401,414],"those":[57,367],"DVd":[60,163,239,307,370],"(data":[62],"cutoff:":[63],"October":[64],"7,":[65,228],"2024).":[66],"Here,":[67],"we":[68],"evaluate":[69],"who":[71,106,125,139,211],"achieved":[72,107,126,140,219],"sustained":[73,108,127,141,220,274,315,383],"for":[79,111],"\u226512":[80,112,201],"months":[81,113,202],"DREAMM-7":[83,149],"describe":[85],"rates,":[87],"demographics,":[88],"baseline":[89,120],"characteristics,":[91],"safety":[93,136],"profiles":[94],"two":[97],"treatment":[98,217,323],"arms.":[99],"Objectives:":[100],"Evaluate":[101,134],"number":[103],"MRD":[109,128,142,172,191,197,221,230,272,276,304,316,384,389,412],"DREAMM-7.":[115,133,147],"Describe":[116],"demographics":[118],"characteristics":[122],"(\u226512":[130,144],"months)":[131,145],"Methods:":[148],"(NCT04246047)":[150],"is":[151],"a":[152,297,328,341],"phase":[153],"3,":[154],"multicenter,":[155],"open-label,":[156],"randomized":[157,209],"(1:1)":[158],"trial":[159],"RRMM":[167],"LOT.":[171],"achieving":[175,234,271,302,382],"\u2265CR":[176,235],"was":[177,193,205,278,294,319],"evaluated":[178],"by":[179,199],"next-generation":[180],"sequencing":[181],"(NGS)":[182],"at":[183,240,338,392,435],"10\u22125":[184,242,393],"10\u22126":[186,249,395],"(exploratory":[187],"analysis)":[188],"sensitivities.":[189],"Sustained":[190],"defined":[194],"as":[195],"\u2265CR-based":[196,275,303,388,411],"NGS":[200],"apart.":[203],"Safety":[204,372],"analyzed":[206],"all":[208,325],"received":[212,358],"dose":[214],"study":[216],"negativity.":[222,385],"Results:":[223],"At":[224],"data":[225],"cutoff":[226],"(October":[227],"2024),":[229],"among":[232],"favored":[236],"over":[238],"[70%":[243],"(61/87)":[244],"59%":[246],"(26/44)]":[247],"[45%":[250],"(39/87)":[251],"23%":[253],"(10/44)]":[254],"thresholds;":[255],"corresponding":[256],"intention-totreat":[257],"(ITT)":[258],"were":[260,374,397,418],"25%":[261],"10%":[263],"16%":[265],"4%,":[267],"respectively.":[268],"Among":[269,312],"negativity,":[273,317],"observed":[279],"57%":[281],"(35/61)":[282],"treated":[285],"42%":[289],"(11/26)":[290],"DVd.":[292,402],"associated":[295],"shorter":[298],"median":[299],"time":[300],"to":[301],"(11.14":[308],"17.02":[310],"months).":[311],"age":[318],"well":[320],"balanced":[321],"across":[322],"arms,":[324],"had":[327,350,424],"Revised":[329],"International":[330],"Staging":[331],"System":[332],"stages":[333],"I":[335],"or":[336],"II":[337],"screening,":[339],"greater":[342],"proportion":[343,405],"group":[349],"highrisk":[351],"cytogenetics":[352],"(40%":[353],"27%,":[355],"respectively)":[356,365],"2+":[359],"LOTs":[361],"(37%":[362],"9%,":[364],"group.":[371],"outcomes":[373],"similar":[375],"between":[376],"ITT":[378],"population":[379],"Conclusions:":[386],"Overall,":[387],"thresholds":[396],"A":[403],"BVd-treated":[407],"also":[409,419],"maintained":[410],"DVd-treated":[415],"more":[420],"heavily":[421],"pretreated":[422],"high-risk":[428],"cytogenetics.":[429],"Funding:":[430],"GSK.":[431],"Prior":[432],"Presentations:":[433],"Presented":[434],"American":[437],"Society":[438],"Hematology":[440],"(ASH)":[441],"Annual":[442],"Meeting":[443],"2025,":[444],"December":[445],"6-9,":[446],"Orlando,":[447],"FL.":[448]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-08-14T00:00:00"}